Inhibrx Biosciences, Inc. (INBX)

NASDAQ: INBX · Real-Time Price · USD

22.96

+1.19 (5.47%)

At close: Jul 14, 2025, 4:00 PM

23.07

+0.11 (0.48%)

After-hours: Jul 14, 2025, 5:24 PM EDT

Inhibrx Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	1,723	1,688	-241.36	-115.33
Depreciation & Amortization	2.6	2.29	1.19	1.23
Other Amortization	1.36	2.07	4.9	-
Loss (Gain) From Sale of Assets	0.01	0.01	0	0.02
Loss (Gain) on Equity Investments	-	-	1.63	-
Stock-Based Compensation	54.57	58.52	24.85	17.79
Other Operating Activities	-1,997	-1,997	0.13	1.62
Change in Accounts Receivable	0.56	0.38	-0.54	0.13
Change in Accounts Payable	13.5	17.9	2.11	-0.38
Change in Unearned Revenue	-	-	-0.17	-1.1
Change in Other Net Operating Assets	34.12	33.77	13.94	5.21
Operating Cash Flow	-167.25	-194.41	-193.31	-90.81
Capital Expenditures	-1.5	-2.6	-4.59	-0.69
Investing Cash Flow	-1.5	-2.6	-4.59	-0.69
Issuance of Common Stock	32.95	71.68	202.32	-
Other Financing Activities	-0.13	-	-0.36	91.5
Financing Cash Flow	132.79	71.68	201.96	91.5
Net Cash Flow	-35.96	-125.33	4.06	-
Free Cash Flow	-168.75	-197.01	-197.9	-91.5
Free Cash Flow Margin	-84376.50%	-98503.00%	-10994.56%	-6957.95%
Free Cash Flow Per Share	-10.93	-13.15	-16.80	-
Cash Interest Paid	5.91	11.51	26.72	-
Cash Income Tax Paid	0	0	0	0
Levered Free Cash Flow	-80.62	-118.26	-106.38	-
Unlevered Free Cash Flow	-76.95	-111.89	-91.38	-
Change in Net Working Capital	-12.67	5.48	-24.17	-

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q